







an Open Access Journal by MDPI

Trends in Pharmacological Treatments for Acute Coronary Syndrome

Guest Editor:

Dr. Olivia Manfrini

School fo Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy

Deadline for manuscript submissions:

closed (31 March 2021)

Message from the Guest Editor

Dear Colleagues,

The rate of mortality associated with ischemic heart disease (IHD) has decreased in Europe over the last few decades; however, IHD remains the single most common cause of death worldwide. Indeed, the in-hospital mortality rates of unselected patients with STEMI vary between 4 and 12%.

Pharmaceuticals is launching a Special Issue on "Trends in Pharmacological Treatments for Acute Coronary Syndrome", which will be dedicated to the following specific issues:

- gender differences;
- MINOCA;
- quality indicators for reducing the gap between optimal guideline-based treatment and actual care;
- non-invasive imaging for acute and long-term management; and
- the special patients subset (patients taking an oral anticoagulant, patients with renal insufficiency, the elderly, etc.)













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us